Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

December 20, 2026

Study Completion Date

December 31, 2027

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

Doxycycline

Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.

DRUG

Placebo

This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.

Trial Locations (2)

00256

NOT_YET_RECRUITING

Makerere University Lung Institute, Kampala

RECRUITING

Mulago National Referral Hospital, Kampala

All Listed Sponsors
collaborator

Makerere University Lung Institute

UNKNOWN

lead

Makerere University

OTHER